Our mission is to develop novel, disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.
Imcyse is pioneering the development of a new class of specific immunotherapeutic vaccines. Our new technology platform is based on the discovery of synthetic peptide vaccines to block the immune processes causing immune-mediated diseases. Imcyse therapeutic vaccines therefore offer the possibility to cure severe chronic diseases for which there is no satisfactory therapeutic alternative. The technology can also prevent the immunogenic responses that weaken the efficiency of chronic therapies.
Our vision is to become the major player in active specific immunotherapy for the curative treatment of autoimmune, allergic, infectious and cancer diseases.